Clinical trial
Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer
NCT00066885 · Novacea, Industry · Completed
Key facts
| NCT number | NCT00066885 |
|---|---|
| Title | Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer |
| Official title | A Phase 1/2 Multicenter, Open Label, Dose Ranging Study of DN-101 and Taxotere® in Patients With Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Previous Therapy With Platinum-Based Chemotherapy |
| Lead sponsor | Novacea, Industry |
| Collaborators | Aventis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | calcitriol + docetaxel |
| Enrollment | 80 |
| Start date | Jun 1, 2003 |
| Completion | Dec 1, 2005 |
| First posted | Aug 8, 2003 |
| Last update posted | May 7, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: